Quantcast
Last updated on April 23, 2014 at 20:01 EDT

Latest Transplantation medicine Stories

2014-03-24 04:22:05

AMSTERDAM, March 24, 2014 /PRNewswire/ -- Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces that it will organize a satellite symposium on March 30, 2014 at the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Milan, Italy. The satellite symposium hosted by Kiadis Pharma is entitled: "Effective T-cell immunotherapy with ATIR(TM) after...

2014-03-18 23:00:52

New sterile option provides tissue banks and tissue processing centers added convenience and safety in their operations. Birmingham, OH (PRWEB) March 18, 2014 Exsurco Medical, Inc. has introduced a single-use, sterile disposable for its Amalgatome® SK Skin Debridement Device, the newest advancement in excision science for tissue banks. Technicians now have the choice of purchasing factory-packaged sterile disposables, or using non-sterile versions that they sterilize in their lab...

2014-03-17 16:28:34

ROSEMONT, Ill., March 17, 2014 /PRNewswire-USNewswire/ -- An individual's appearance and facial features are largely dictated by their bone structure. For patients who have experienced injury or disease leading to the damage or loss of bone in their face, the standard method of treatment is to use a large bone graft or metal implant to replace their damaged bone. Unfortunately, these treatment options are unlikely to result in something closely resembling the original bone...

2014-03-15 08:21:40

In the news release, U.S. FDA Accepts Veloxis' New Drug Application for Envarsus® for the Prevention of Organ Rejection in Kidney Transplant Patients, issued 13-Mar-2014 by Veloxis Pharmaceuticals, we are advised that the first bullet should read "FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA) of October 30, 2014" rather than "October 3, 2014" as originally issued inadvertently. The complete, corrected release follows: U.S. FDA Accepts Veloxis' New Drug...

2014-03-13 16:27:23

Decision Alleviates Concerns Over Potential for Organ Rejections, Preserves Physician Discretion Over Patient Care WASHINGTON, March 13, 2014 /PRNewswire-USNewswire/ -- Kidney Care Partners (KCP) voiced strong support for Centers for Medicare & Medicaid Services (CMS) Administrator Marilyn Tavenner's announcement that CMS would not finalize proposals to lift the protected class definition on three drug classes, including life-sustaining immunosuppressive drugs, that transplant...

2014-03-13 16:27:19

HORSHOLM, Denmark, March 13, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) today announced the U.S. FDA accepted for standard review the company's New Drug Application (NDA) for Envarsus(®) for the prevention of organ rejection in adult kidney transplant patients. Envarsus(®) is Veloxis' once-daily tacrolimus based on the company's proprietary MELTDOSE technology. Key points: -- FDA has set a target review date under the Prescription Drug User Fee Act (PDUFA)...

2014-03-12 20:24:35

DUBLIN, March 12, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/4v88mx/bone_grafts) has announced the addition of the "Bone Grafts - Global Strategic Business Report" [http://www.researchandmarkets.com/research/4v88mx/bone_grafts ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report analyzes the worldwide markets for Bone Grafts in US$ Million. The US market for Bone Graft...

2014-03-11 16:26:18

Results provide significant support to advance i-FACTOR(TM) Peptide Enhanced Bone Graft for FDA regulatory review. WESTMINSTER, Colo., March 11, 2014 /PRNewswire/ -- Cerapedics, Inc., an orthobiologics company focused on developing and commercializing novel peptide enhanced bone graft products based on its proprietary synthetic small peptide (P-15) technology platform, today presented preliminary outcomes data from a FDA Investigational Device Exemption (IDE) clinical trial for...

2014-03-11 16:25:46

EDISON, N.J., March 11, 2014 /PRNewswire/ -- The Musculoskeletal Transplant Foundation (MTF), the world's leading tissue bank today announced the recipients of its 2014 Research Grants. Since 1987, MTF has been at the forefront of research focused on the transplantation of donated human tissue, with approximately $38 million awarded through 2013. MTF anticipates awarding close to $2 million in grants and awards in the 2014 calendar year. The 2014 grant recipients approved for...

2014-03-07 23:21:07

OTTR™ Chronic Care Solutions, the leader in transplant patient tracking and data management software, is proud to announce that they have received official certification from the Center for International Blood and Marrow Transplant Research (CIBMTR) and the National Marrow Donor Program (NMDP) to submit, and retrieve, data using the AGNIS application and framework. Omaha, NE (PRWEB) March 07, 2014 The CIBMTR provides a unique resource of data for addressing important issues in...


Latest Transplantation medicine Reference Libraries

Bone Marrow Transplantation (journal)
2012-06-04 20:00:41

Bone Marrow Transplantation is a peer-reviewed medical journal published monthly by Nature Publishing Group. As of May 2012, the editor-in-chief is J.M. Goldman (UK). The journal publishes high quality, original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation in humans. The broad scope of the journal thus encompasses topics such as stem cell biology, kinetics and cytokine control, transplantation immunology, HLA and matching...

More Articles (1 articles) »